Serina Therapeutics (SER) risk factors

87 risks, 14 new, 7 dropped, 10 reworded since the prior year. Serina Therapeutics faces going concern doubts due to cash deficits and received a NYSE American delisting warning for low equity. The company relies entirely on third-party vendors for clinical trials and manufacturing while managing a tiny team of 16 employees.

80 risks. Serina Therapeutics relies entirely on its unproven POZ Platform drug delivery technology for preclinical pipeline development. The company faces persistent operating losses, total revenue absence, and a critical need for external financing. Regulatory hurdles, reliance on third-party manufacturers, and intellectual property protection dominate the risk profile.